$3.05
7.29% today
Nasdaq, Apr 03, 06:34 pm CET
ISIN
CH1125843347
Symbol
SOPH

SOPHiA Genetics SA Stock price

$3.29
-0.28 7.84% 1M
-0.24 6.80% 6M
+0.22 7.17% YTD
-1.67 33.67% 1Y
-4.37 57.05% 3Y
-13.47 80.37% 5Y
-13.47 80.37% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.12 3.79%
ISIN
CH1125843347
Symbol
SOPH

Key metrics

Market capitalization $219.87m
Enterprise Value $169.67m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.60
P/S ratio (TTM) P/S ratio 3.37
P/B ratio (TTM) P/B ratio 2.27
Revenue growth (TTM) Revenue growth 4.49%
Revenue (TTM) Revenue $65.17m
EBIT (operating result TTM) EBIT $-66.75m
Free Cash Flow (TTM) Free Cash Flow $-43.23m
Cash position $80.23m
EPS (TTM) EPS $-0.95
P/E forward negative
P/S forward 2.99
EV/Sales forward 2.31
Short interest 0.10%
Show more

Is SOPHiA Genetics SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

SOPHiA Genetics SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a SOPHiA Genetics SA forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a SOPHiA Genetics SA forecast:

Buy
83%
Hold
17%

Financial data from SOPHiA Genetics SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
65 65
4% 4%
100%
- Direct Costs 21 21
9% 9%
33%
44 44
2% 2%
67%
- Selling and Administrative Expenses 68 68
8% 8%
104%
- Research and Development Expense 34 34
7% 7%
53%
-58 -58
14% 14%
-89%
- Depreciation and Amortization 8.60 8.60
3% 3%
13%
EBIT (Operating Income) EBIT -67 -67
12% 12%
-102%
Net Profit -62 -62
21% 21%
-96%

In millions USD.

Don't miss a Thing! We will send you all news about SOPHiA Genetics SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SOPHiA Genetics SA Stock News

Neutral
PRNewsWire
16 days ago
BOSTON, MA and ROLLE, Switzerland , March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable i...
Neutral
Seeking Alpha
30 days ago
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q4 2024 Earnings Call March 4, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Mark Massaro - BTIG Tejas Savant - Morgan Stanley Bill Bonello - Cr...
Neutral
PRNewsWire
about one month ago
BOSTON and ROLLE, Switzerland , March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million, up 4% year-over-year or 6% on a constant currency basis excluding COVI...
More SOPHiA Genetics SA News

Company Profile

SOPHiA GENETICS SA is a healthcare technology company, which establishes the practice of data driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Head office Switzerland
CEO Jurgi Camblong
Employees 423
Founded 2011
Website www.sophiagenetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today